We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App




Next-Generation qPCR System Enhances Capabilities for Accurate Patient Diagnosis and Effective Clinical Decisions

By LabMedica International staff writers
Posted on 28 Nov 2023

In response to the evolving needs of healthcare systems, particularly post-pandemic, a next-generation qPCR system offers the flexibility to switch seamlessly between research and clinical applications. More...

The new system with key features such as gold standard technology essential for accurate patient diagnosis and making informed clinical decisions, can aid advancement of personalized healthcare and enhancing preparedness for outbreaks.

Roche Diagnostics (Basel, Switzerland) has launched the LightCycler PRO System which builds upon the proven gold standard technology of the LightCycler real-time PCR Systems, a product line being developed by Roche since the introduction of their first system in 1998. Real-time PCR, or qPCR, is a method that enables simultaneous amplification and detection of DNA in real-time. The LightCycler systems are renowned for their dependable performance, and the LightCycler PRO System is the most advanced and adaptable iteration yet. It is uniquely designed for both research and in vitro diagnostic (IVD) workflows, allowing laboratories to transition smoothly from research to clinical testing of patient samples.

The LightCycler PRO System incorporates several enhancements, such as a new vapor chamber that ensures uniform temperature distribution, improved software algorithms, and a completely revamped software and user interface. These upgrades make it the most sophisticated LightCycler System Roche has ever released. This addition to Roche’s molecular PCR testing range offers tools for a wide array of professionals, from researchers to those conducting patient tests for conditions like cancer and infectious diseases. The system enables the development of custom tests and supports more than 200 LightMix Modular research assays and over 60 LightMix CE-IVD assays from Roche’s subsidiary, TIB Molbiol. Scheduled to launch in select countries by the end of 2023, the system will be CE-marked and have an FDA 510(k) exempt status, with further expansion into more countries on the cards.

“Roche has made significant contributions in establishing and advancing PCR technology to address the needs of healthcare systems,” said Josh Lauer, Head of Molecular Labs at Roche Diagnostics. “We have listened to laboratories and hospitals, and implemented their feedback, which has driven important design improvements. Healthcare systems have experienced significant resource constraints and rapidly shifting dynamics post-pandemic. The LightCycler PRO addresses those dynamics by offering the flexibility to switch seamlessly between research and clinical applications.”

Related Links:
Roche Diagnostics 


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
ESR Analyzer
TEST1 2.0
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.